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Comments to the Author
The reviewer appreciated the opportunity to be invited to read and revise the manuscript. However, the reviewer just felt it would be much convenient to do the review if the editorial provides line numbers to the article, especially to such as a long review article. Overall, the manuscript was well written, and the citations were comprehensive. Actually, all the references were checked manually to ensure correct citation. Minor revisions: 1. Page 3 (Introduction), 3rd paragraph: "as promising biomarkers 8." Need format revision. 2. Page 4 (Aberrant miRNA expressions and roles in CRC), 1st paragraph: please make sure [23] is the right reference; may include the Decision letter (RSOB-18-0212.R0)
17-Dec-2018
Dear Professor Liang,
We are pleased to inform you that your manuscript RSOB-18-0212 entitled "Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis" has been accepted by the Editor for publication in Open Biology. The reviewer(s) have recommended publication, but also suggest some minor revisions to your manuscript. Therefore, we invite you to respond to the reviewer(s)' comments and revise your manuscript.
Please submit the revised version of your manuscript within 14 days. If you do not think you will be able to meet this date please let us know immediately and we can extend this deadline for you.
To revise your manuscript, log into https://mc.manuscriptcentral.com/rsob and enter your Author Centre, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.
You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, please revise your manuscript and upload a new version through your Author Centre.
When submitting your revised manuscript, you will be able to respond to the comments made by the referee(s) and upload a file "Response to Referees" in "Section 6 -File Upload". You can use this to document any changes you make to the original manuscript. In order to expedite the processing of the revised manuscript, please be as specific as possible in your response to the referee(s). Please see our detailed instructions for revision requirements https://royalsociety.org/journals/authors/author-guidelines/.
Before uploading your revised files please make sure that you have:
1) A text file of the manuscript (doc, txt, rtf or tex), including the references, tables (including captions) and figure captions. Please remove any tracked changes from the text before submission. PDF files are not an accepted format for the "Main Document".
2) A separate electronic file of each figure (tiff, EPS or print-quality PDF preferred). The format should be produced directly from original creation package, or original software format. Please note that PowerPoint files are not accepted.
3) Electronic supplementary material: this should be contained in a separate file from the main text and meet our ESM criteria (see http://royalsocietypublishing.org/instructionsauthors#question5). All supplementary materials accompanying an accepted article will be treated as in their final form. They will be published alongside the paper on the journal website and posted on the online figshare repository. Files on figshare will be made available approximately one week before the accompanying article so that the supplementary material can be attributed a unique DOI.
Online supplementary material will also carry the title and description provided during submission, so please ensure these are accurate and informative. Note that the Royal Society will not edit or typeset supplementary material and it will be hosted as provided. Please ensure that the supplementary material includes the paper details (authors, title, journal name, article DOI Comments to the Author(s) The manuscript entitled "Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis" reviewed the latest progress of potential applications of microRNA as biomarkers for the diagnosis and prognosis of colorectal cancer (CRC). The authors also discussed the advantages of using microRNA as biomarkers and the technical progresses in microRNA detection. This manuscript is well organized. The topic and content are attractive, providing a very good literature resource for understanding the progress of microRNA research in cancer studies. The manuscript may be accepted for publication in the journal when several issues are properly addressed or corrected. 1. It would be better if the disadvantages of using microRNA as biomarkers are also summarized and discussed in the section subtitled "Advantages of microRNA biomarkers" on page 8. 2. Is the list of microRNA biomarkers specific for CRC? Can any of them be applied to other types of cancers? 3. Some sentences are not clear. For example: On the line 7, page 5, the sentence "Regarding to lymph node metastasis, although a previous evaluation about the correlations of miRNA expression patterns with CRC tumor stage by using miRNA microarrays showed no significant differences". On the line 24, page 5, the sentence "Furthermore, miRNAs have great potential in CRC treatment and the overcome of resistance to cancer therapy " is difficult to understand.
4. Abbreviations should be consistency in the manuscript. For example, the miRNA and microRNA. On the line 14, page 8, the form of the letter "p" (p &lt; 0.001 and P = 0.004).
Referee: 2
Comments to the Author(s) The reviewer appreciated the opportunity to be invited to read and revise the manuscript. However, the reviewer just felt it would be much convenient to do the review if the editorial provides line numbers to the article, especially to such as a long review article. Overall, the manuscript was well written, and the citations were comprehensive. Actually, all the references were checked manually to ensure correct citation. Decision letter (RSOB-18-0212.R1)
02-Jan-2019
Dear Professor Liang
We are pleased to inform you that your manuscript entitled "Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis" has been accepted by the Editor for publication in Open Biology.
You can expect to receive a proof of your article from our Production office in due course, please check your spam filter if you do not receive it within the next 10 working days. Please let us know if you are likely to be away from e-mail contact during this time.
Article processing charge Please note that the article processing charge is immediately payable. A separate email will be sent out shortly to confirm the charge due. The preferred payment method is by credit card; however, other payment options are available.
Thank you for your fine contribution. Here, our point-by-point responses to the reviewers' comments were integrated into the revised manuscript as enumerated below.
Referee 1 Comment 1. It would be better if the disadvantages of using microRNA as biomarkers are also summarized and discussed in the section subtitled "Advantages of microRNA biomarkers" on page 8.
Response:
We agree with the reviewer's good suggestion. In the revised version, we have added the concerns of disadvantages and specificity of microRNA biomarkers for CRC on page 9.
Comment 2. Is the list of microRNA biomarkers specific for CRC? Can any of them be applied to other types of cancers?
Response: Some predictive candidate miRNAs biomarkers are not specific for CRC, which are also reported to have diagnosis potentials for other kind of cancers. Fortunately, a panel of miRNAs can be used to distinguish CRC patients from healthy controls with a relative high sensitivity and specificity by testing in a large population of subjects. Therefore several miRNAs combinations are feasible to monitor cancer profiling. We have summarized and discussed the specificity of microRNA biomarkers for CRC on page 9. 
We have carefully modified the language expression of the whole manuscript and made them easier to understand.
